Skip to content

US · INCY · BIOTECHNOLOGY

Incyte Corporation (INCY) intrinsic value and stock valuation

$114.63as of 2026-11-21 · Mkt cap 24.44B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Incyte Corporation DCF and intrinsic value

InvestorsCraft values INCY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INCY’s statements →

Incyte Corporation Graham Number

Graham Number: $62.66d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Wilmington, DE 19803 incyte.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$5.14B+14% 5y CAGRd
20112025
Net income
$1.29B
20112025
Free cash flow
$1.35B
20112025
Total equity
$5.17B+14.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$5.14B$4.24B$3.7B$3.39B$2.99B
Operating income$1.34B$101.3M$655.4M$591.6M$585.8M
Net income$1.29B$32.6M$597.6M$340.7M$948.6M
EPSd$6.41M$154.9K$2.65M$1.52M$4.27M
Operating cash flow$1.41B$335.3M$496.5M$969.9M$749.5M
Capital expenditure-$-58.87M-$-86.26M-$-47.49M-$-77.83M-$-181.01M
Free cash flow$1.35B$249.1M$449M$892.1M$568.5M
Total assets$6.96B$5.44B$6.78B$5.84B$4.93B
Total debt$69.4M$43.5M$38.3M$41.5M$44.8M
Net debt-$-3.03B-$-1.64B-$-3.18B-$-2.91B-$-2.01B
Total equity$5.17B$3.45B$5.19B$4.37B$3.77B
Cash and short-term investments$3.58B$2.16B$3.66B$3.24B$2.35B
Income statement
20252024202320222021
Revenue$5.14B$4.24B$3.7B$3.39B$2.99B
Cost of revenue$372.1M$312.1M$255M$207M$151M
Gross profit$4.77B$3.93B$3.44B$3.19B$2.84B
Research and development expenses$2.05B$2.61B$1.63B$1.59B$1.46B
Selling, general and administrative expenses$1.38B$1.22B$1.16B$1B$739.6M
Other expenses$0.00-$-1.02M$2.04M$7.97M$51.8M
Operating expenses$3.43B$3.83B$2.79B$2.6B$2.25B
Cost and expenses$3.8B$4.14B$3.04B$2.8B$2.4B
Interest income$105.6M$128.7M$0.00$0.00$0.00
Interest expense$2.43M$2.28M$2.55M$2.67M$1.91M
Depreciation and amortization$93.3M$89.3M$82.7M$67.9M$57.8M
Ebitda$1.76B$408.2M$919.4M$599.6M$630.2M
Operating income$1.34B$101.3M$655.4M$591.6M$585.8M
Total other income/expenses, net$321.7M$215.3M$178.9M-$-62.51M-$-15.33M
Income before tax$1.66B$316.6M$834.2M$529.1M$570.4M
Income tax expense$377.8M$284M$236.6M$188.5M-$-378.14M
Net income$1.29B$32.6M$597.6M$340.7M$948.6M
Weighted average shares outstanding$195.2M$207.1M$223.6M$222M$220.4M
Weighted average diluted shares outstanding$200.7M$210.5M$225.9M$224M$222.1M
Balance sheet
20252024202320222021
Cash and short-term investments$3.58B$2.16B$3.66B$3.24B$2.35B
Net receivables$1.02B$853.2M$743.6M$644.9M$616.3M
Inventory$101.1M$58.9M$63M$42M$27.9M
Total current assets$5.02B$3.24B$4.65B$4.09B$3.12B
Property, plant and equipment, net$758.4M$794.2M$777.1M$765.6M$751.5M
Goodwill and intangible assets$250.1M$269.4M$279.1M$284.8M$306.4M
Long-term investments$48M$18.8M$187.7M$133.7M$221.3M
Total non-current assets$1.52B$2.21B$2.14B$1.75B$1.81B
Total assets$6.96B$5.44B$6.78B$5.84B$4.93B
Accounts payable$209.9M$197.5M$109.6M$277.6M$172.1M
Short-term debt$10.2M$10M$9.12M$11.4M$13.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.52B$1.64B$1.24B$1.16B$854.3M
Long-term debt$59.2M$33.5M$29.2M$30.1M$31.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$288.2M$354.9M$351.9M$313.8M$309M
Capital lease obligations$44.7M$43.5M$38.3M$41.5M$44.8M
Total liabilities$1.8B$2B$1.59B$1.47B$1.16B
Common stock$200K$190K$220K$220K$220K
Retained earnings$213.8M-$-1.07B$160.4M-$-437.21M-$-777.87M
Accumulated other comprehensive income (loss)$25.5M-$-13.12M$13.1M$15.1M-$-19.45M
Total equity$5.17B$3.45B$5.19B$4.37B$3.77B
Total investments$530.8M$489.1M$630.4M$421.2M$512M
Total debt$69.4M$43.5M$38.3M$41.5M$44.8M
Net debt-$-3.03B-$-1.64B-$-3.18B-$-2.91B-$-2.01B
Cash flow statement
20252024202320222021
Net income$1.29B$32.6M$597.6M$340.7M$948.6M
Depreciation and amortization$93.3M$89.3M$82.7M$67.9M$57.8M
Stock-based compensation$249.4M$266.1M$215.9M$188.4M$183M
Change in working capital-$-527.16M$138.2M-$-248.65M$198.8M-$-14.57M
Accounts receivable-$-170.77M-$-111.59M-$-98.68M-$-28.58M-$-134.31M
Inventory-$-58.51M-$-127.63M-$-170.15M-$-67.5M-$-20.96M
Accounts payable$6.56M$88.2M-$-167.94M$105.4M$73.3M
Net cash provided by operating activities$1.41B$335.3M$496.5M$969.9M$749.5M
Investments in property, plant and equipment-$-58.87M-$-86.26M-$-47.49M-$-77.83M-$-181.01M
Acquisitions, net$0.00$0.00$47.5M$710K$181M
Net cash used for investing activities-$-102.61M$157.5M-$-207.68M-$-78.54M-$-207.7M
Common stock issued$221.8M$49.3M$35.8M$61.1M$58.6M
Common stock repurchased-$-19.1M-$-2B$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$101M-$-2.02B-$-20.03M-$-790K$6.18M
Net change in cash$1.41B-$-1.53B$262.1M$894M$544.4M
Cash at end of period$3.1B$1.69B$3.22B$2.95B$2.06B
Operating cash flow$1.41B$335.3M$496.5M$969.9M$749.5M
Capital expenditure-$-58.87M-$-86.26M-$-47.49M-$-77.83M-$-181.01M
Free cash flow$1.35B$249.1M$449M$892.1M$568.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Incyte Corporation

        Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

        CEO
        William J. Meury
        Employees
        2.84K
        Beta
        0.76

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Incyte Corporation (INCY)?

        Incyte Corporation (INCY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INCY undervalued?

        INCY trades at a price of $114.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.